Bristol Myers Squibb (BMS) is banking on a nuclear development pipeline to overcome the patent cliff by 2030 after the patents on Opdivo and Eliquis[1][2] expire. These two drugs accounted for more than half of the company's total revenue of $35.7 billion as of September 30, 2025[1]. Despite their year-on-year growth of 8%, total sales fell by 1%, which shows the pressure on the core portfolio[1]. In 2026, BMS expects key results for six assets to deliver earnings[1]. The company focuses on a diversified portfolio in oncology, cardiovascular diseases and neurosciences, strengthened by the acquisition of Karuna Therapeutics[2]. In 2026, it confirms progress after two years of stabilization, with an emphasis on pipeline execution and commercial potential[2]. BMS invests $9 billion a year in research and innovation, which represents a fifth of its turnover[6]. The pipeline includes dozens of clinical studies, especially in oncology[1].